AaRS- inhibiittorikehittelystä vuoden 2020 uutinen

https://www.sciencedirect.com/science/article/abs/pii/S0223523419310931?via%3Dihub

Discovery of novel tRNA-amino acid dual-site inhibitors against threonyl-tRNA synthetase by fragment-based target hopping

Author links open overlay panel JunsongGuo¹BingyiChen et al.

 https://doi.org/10.1016/j.ejmech.2019.111941

Mitä merkitystä kliiniselle lääketieteelle olisi tämän kaltaisista inhibiittoriesta muuten kuin  laboratoriotutkimuksiin ja aminohappometabolian selvitelyyn ja ulkoiseen käyttöön?

Highlights

•New ThrRS inhibitors were designed by using a fragment-based target hopping strategy.

•Compound 30d exhibited significant enzyme inhibition and antibacterial activities.

•Crystallography revealed a unique ATP-independent dual-site inhibitory mode of 30d.

•The target hopping strategy could be applied to discover inhibitors for other aaRSs.

Threonyl-tRNA synthetase (ThrRS) is a key member of the aminoacyl-tRNA synthetase (aaRS) family that plays essential roles in protein biosynthesis, and ThrRS inhibitors have potential in the therapy of multiple diseases, such as microbial infections and cancers. Based on a unique tRNA-amino acid dual-site inhibitory mechanism identified recently with the herb-derived prolyl-tRNA synthetase (ProRS) inhibitor halofuginone (HF), a series of compounds have been designed and synthesized by employing a fragment-based target hopping approach to simultaneously target the tRNA^Thr and l-threonine binding pockets of ThrRS. Among them, compound 30d showed an IC₅₀ value of 1.4 μM against Salmonella enterica ThrRS (SeThrRS) and MIC values of 16–32 μg/mL against the tested bacterial strains. The cocrystal structure of SeThrRS in complex with 30d was determined at high resolution, revealing that 30d simultaneously occupies both binding pockets for the nucleotide A76 of tRNA^Thr and l-threonine in an ATP-independent manner, a novel mechanism compared to all other reported ThrRS inhibitors. Our study provides a new class of ThrRS inhibitors, and more importantly, it presents the first experimental evidence that the tRNA-amino acid dual-site inhibitory mechanism could apply to other aaRSs beyond ProRS, thus providing great opportunities for designing new mechanistic inhibitors for aaRS-based therapeutics.